GlaxoSmithKline sets $1.6B in new cost cuts, thanks in part to Advair's U.S. formulary discounts

Brace yourselves for layoffs at GlaxoSmithKline ($GSK). The saga is familiar: An aging blockbuster loses steam to competing meds, and its maker gets out the cost-cutting ax to compensate. This time, the faltering drug is Advair, which adds some new twists to the story--including a warning to the whole pharma industry about formulary placement. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.